Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1913 - 1920 of 11449 results
Department of Homeland Security Designates Ukraine and Afghanistan for TPS
March 29, 2022| Alert| Viewpoint
PBM Regulatory Roundup (Spring 2022): The 8th Circuit Rules and More States Issue Regulations
March 29, 2022| Blog| Viewpoint
USCIS Conducts Lottery Selection Process for H-1B FY2023 Cap
March 28, 2022| Alert| Viewpoint
Federal Healthcare Agencies Aim to Prioritize Information Blocking Enforcement in 2022
March 28, 2022| Blog| Viewpoint
Six Common Contract Traps: A Field Guide
March 25, 2022| Advisory| Viewpoint
Alumni Profile: Geri Rochino of 10x Genomics
March 25, 2022| Article| Viewpoint
Healey Names Lawyer As Campaign Manager
March 24, 2022| News
News & Press Releases
Venture Mega-Rounds Return to Biotech
September 26, 2024
Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.
Lenovo’s Setback in Ericsson ITC Case May Impact Other SEP Disputes
September 26, 2024
Intellectual Property Division Chair Michael Renaud was quoted by IAM in an article about the ITC case between Ericsson and Lenovo and its potential implications for FRAND negotiations. While most ITC cases involving Standard Essential Patents (SEPs) have resulted in no violation findings, this case could change that.
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.